Thyrotropin-producing pituitary adenoma simultaneously existing with Graves’ disease: a case report

Nobuhiko Arai 1*, Makoto Inaba 1, Takamasa Ichijyo 2, Hiroshi Kagami 1 and Yutaka Mine 1

Abstract

Background: Thyrotropin-producing pituitary tumor is relatively rare. In particular, concurrent cases associated with Graves’ disease are extremely rare and only nine cases have been reported so far. We describe a case of a thyrotropin-producing pituitary adenoma concomitant with Graves’ disease, which was successfully treated.

Case presentation: A 40-year-old Japanese woman presented with mild signs of hyperthyroidism. She had positive anti-thyroid-stimulating hormone receptor antibody, anti-thyroglobulin antibody, and anti-thyroid peroxidase antibody. Her levels of serum thyroid-stimulating hormone, which ranged from low to normal in the presence of high levels of serum free thyroid hormones, were considered to be close to a state of syndrome of inappropriate secretion of thyroid-stimulating hormone. Magnetic resonance imaging showed a macropituitary tumor. The coexistence of thyrotropin-producing pituitary adenoma and Graves’ disease was suspected. Initial therapy included anti-thyroid medication, which was immediately discontinued due to worsening symptoms. Subsequently, surgical therapy for the pituitary tumor was conducted, and her levels of free thyroid hormones, including the thyroid-stimulating hormone, became normal. On postoperative examination, her anti-thyroid-stimulating hormone receptor antibody levels decreased, and the anti-thyroglobulin antibody became negative. The coexistence of thyrotropin-producing pituitary adenoma and Graves’ disease is rarely reported. The diagnosis of this condition is complicated, and the appropriate treatment strategy has not been clearly established.

Conclusions: This case suggests that physicians should consider the coexistence of thyrotropin-producing pituitary adenoma with Graves’ disease in cases in which thyroid-stimulating hormone values range from low to normal in the presence of thyrotoxicosis, and the surgical treatment of thyrotropin-producing pituitary adenoma could be the first-line therapy in patients with both thyrotropin-producing pituitary adenoma and Graves’ disease.

Keywords: Graves’ disease, Pituitary neoplasms, Thyrotropin, Endoscopy, Neurosurgery, TSHoma, TSH-producing tumor

Background

Thyrotropin-producing pituitary adenoma (TSHoma) is a very rare disease, representing less than 1% of all pituitary tumors [1, 2]. Graves’ disease is a common autoimmune endocrinological disorder. Although these diseases manifest similar symptoms of thyrotoxicosis, the treatment for each disease is very different. Up to now (August 2016), nine cases of TSHoma associated with Graves’ disease have been reported [3–10]. In some of those reports, the coexistence of these two diseases made the diagnosis and treatment complicated; thus, thyrotoxicosis was insufficiently controlled. Here we describe an extremely rare case of TSHoma simultaneously existing with Graves’ disease in which an anti-thyroid drug exacerbated the patient’s symptom; however, pituitary surgery was successful.

Case presentation

A 40-year-old Japanese woman presented to a hospital because of a headache in 2004. A magnetic resonance image (MRI) showed one adenoma on her pituitary gland that measured 4×7 mm. Her levels of pituitary anterior lobe hormones were normal. Thus, the tumor was thought to be non-functioning. Thereafter, the tumor
was followed yearly with MRI to determine whether it was growing. In September 2009, periodic MRI showed that the pituitary tumor had become larger. She was referred to our hospital for further evaluation. She had no remarkable history or medications. She had a family history of rheumatoid arthritis. On physical examination, her blood pressure was 127/75 mmHg, and her pulse was regular at 105 beats/minute. Her body temperature was 36.8 °C, height was 163.7 cm, body weight was 53.8 kg, and body mass index was 20.1 kg/m². Her consciousness was alert. She had no neck goiter or leg edema. Both Achilles’ tendon reflexes were moderately increased. She had mild exophthalmos. She denied any headaches or visual field defect. Her other clinical symptoms were not notable. An endocrinological examination and thyroid echocardiography were performed because of hyperthyroidism; in particular, Graves’ disease was suspected. Her serum free triiodothyronine (FT3) level was 6.3 pg/mL (normal 2.3 to 4.0 pg/mL), free thyroxine (FT4) level was 2.3 ng/dL (normal 0.9 to 1.7 ng/dL), thyroid-stimulating hormone (TSH) level was 0.27 μIU/mL (normal 0.5 to 5.0 μIU/mL), anti-TSH receptor antibody (TRAb) was positive (5.0 IU/L, normal <1.0 IU/L), anti-thyroglobulin antibody (TgAb) was positive (2.3 IU/mL, normal <0.3 IU/mL), and anti-thyroid peroxidase antibody (TPOAb) was positive (4.6 IU/mL, normal <0.3 IU/mL). Ultrasonography showed a moderately hypervascular thyroid without any nodes. Due to the increase in her FT3 and FT4 levels, and the decrease in her TSH level and TRAb positivity, Graves’ disease was diagnosed, and anti-thyroid drug therapy was started in April 2010. Subsequently, she stopped taking her medication because she felt that the headache and sweating were exacerbated. In Graves’ disease, the TSH level is normally suppressed by negative feedback due to an increase in the FT3 and FT4 levels; the TSH value falls below the detectable level (<0.1 μIU/mL according to second-generation TSH chemiluminometric assays). In our case, our patient’s TSH value ranged from 0.1 to 0.5 for the 6 months before she started the medication. We suspected that this case was close to being in a state of syndrome of inappropriate secretion of TSH (SITSH), although in SITSH, the TSH values are generally increased.

The simultaneous coexistence of TSHoma was highly suspected. A pituitary MRI showed a less enhanced area in the sella turcica (10×13 mm). On graphical examination, the tumor appeared to be slightly invading her right lateral cavernous sinus (Fig. 1). An anterior pituitary hormone stimulation test indicated that only the TSH had an impaired response to a TSH-releasing hormone (TRH) stimulation test.

Endoscopic trans-sphenoidal neurosurgery was performed for the pituitary adenoma in January 2011. Immediately postoperatively, her TSH values decreased below the detection limit (<0.1 μIU/mL) [11], and her FT3 and FT4 levels became within normal range. A histological examination showed that immunostaining was 99% positive for TSH-β (Figs. 2 and 3). Postoperatively, her TSH levels gradually became normal, and her FT3 and FT4 levels did not increase until February 2016. Her symptom disappeared. TRAb continued to be positive; however, her level of TRAb decreased. TgAb became negative, whereas TPOAb continued to be positive.

**Discussion**

TSHomas are a rare cause of hyperthyroidism, and they account for less than 1% of all pituitary adenomas [1, 2, 10]. They often manifest with mild symptoms of thyrotoxicosis, and they are associated with abnormal levels of thyroid hormones and TSH [10]. Although the levels
Fig. 2 Levels of the anti-thyroid-stimulating hormone receptor antibody, thyroid-stimulating hormone, and free thyroxine. The free thyroxine level was above 1.5 ng/dL preoperatively. Total resection of the pituitary adenoma by endoscopic trans-sphenoidal neurosurgery was performed in January 2011. The free thyroxine level decreased within normal range. Subsequently, the euthyroid status was maintained. In the meantime, the thyroid-stimulating hormone value of a typical patient with Basedow’s disease is less than 0.1 μIU/mL. In the case of syndrome of inappropriate secretion of thyroid-stimulating hormone, the thyroid-stimulating hormone value is more than 0.5 μIU/mL. The present case did not fit either of these two diseases. On postoperative examination, the thyroid-stimulating hormone value decreased below the detection threshold. Gradually, the thyroid-stimulating hormone values became normal. Anti-thyroid-stimulating hormone receptor antibody was continuously above the upper limit of normal range. FT4 free thyroxine, TRAb anti-thyroid-stimulating hormone receptor antibody, TSH thyroid-stimulating hormone.

Fig. 3 Pathological diagnosis of pituitary adenoma was determined (a). Immunostaining showed the following: thyroid-stimulating hormone, strongly positive (b); follicle stimulating hormone, weakly positive; luteinizing hormone, negative; growth hormone, focally positive; prolactin, focally positive; and adenocortrophic hormone, negative.
deficit. We analyzed the TR-β mechanism of RTH is a thyroid hormone receptor (TR) - SITSH indicates the possibility of TSHoma and syn-
of FT3 and FT4 increase, the TSH levels are not sup-
Arai et al. Journal of Medical Case Reports (2017) 11:9

TSHoma associated with Graves’ disease is extremely rare. We searched PubMed for cases of TSHoma associ-
Only nine cases (written in English) have been reported so far (August 2016) [3–10]. In four cases, TSHoma pre-
In two cases, Graves’ disease occurred prior to the onset of TSHoma [8, 9]. In the other three cases, Graves’ disease and TSHoma probably coexisted at the initial diagnosis, as in our case [5, 8, 10].

The treatment for TSHoma concomitant with Graves’ disease is complicated, because the treatment of Graves’ disease is very different from that of TSHoma. As previously mentioned, three cases with both TSHoma and Graves’ disease have been reported. In all these cases, anti-thyroid medication was chosen first to treat Graves’ disease. However, the medication failed to normalize the FT4, FT3, and TSH levels, resulting in the progression of TSHoma. The reason for this is because anti-thyroid therapy inhibits negative feedback to TSH, just as anti-

Subsequently, her TSH value decreased below the de-
table minimum limit, and it gradually normalized. Her FT3 and FT4 levels became normal immediately postoperatively. Her subjective symptom disappeared. Of interest, her TRAb levels decreased, TgAb became nega-
tive, and Graves’ hyperthyroidism has not occurred since the operation. The cause of postoperative remission of Graves’ hyperthyroidism is not clear. However, these ob-

TSH plays an important role in the maintenance of normal physiology and in the regulation of immuno-

In any case, the surgical treatment of TSHoma may be considered the first choice in patients with both TSHoma and Graves’ disease to prevent the risk of pro-
moting TSHoma by anti-thyroid therapy. Conversely, some reports have shown that Graves’ disease has subse-
sequently occurred after TSHoma is treated. In one case, it was suggested that a rapid reduction in the TSH levels postoperatively induced apoptosis and activated an auto-
immune response against the thyroid gland. The mecha-
nism is the increased expression of various cell surface markers on thyrocytes [7]. Hence, physicians should pay attention to the development of Graves’ disease after TSHoma is treated, especially in cases with concomitant Graves’ disease.

Conclusions
The present case demonstrated that trans-sphenoidal surgery, which is the standard therapy for TSHoma, should be considered first-line therapy in patients with both TSHoma and Graves’ disease. Then, when Graves’ disease becomes active, anti-thyroid therapy should be started as second-line therapy. Moreover, a definitive op-
eration is needed to prevent the subsequent treatment from becoming complicated.

Abbreviations
FT3: Free triiodothyronine; FT4: Free thyroxine; MRI: Magnetic resonance image; RTH: Resistance to thyroid hormone; SITSH: Syndrome of inappropriate secretion of TSH; TgAb: Anti-thyroglobulin antibody; TPOAb: Anti-thyroid peroxidase antibody; TR: Thyroid hormone receptor; TRAb: Anti-Thyroid-stimulating hormone receptor antibody; TRH: Thyroid-
stimulating hormone-releasing hormone; TSH: Thyroid-stimulating hormone; TSHoma: Thyrotropin-producing pituitary adenoma
Acknowledgements
We acknowledge Dr Shimokawa of the Department of Pathology at Saiseikai Yokohamashi Tobu Hospital for helping with the pathological examinations. We also acknowledge Dr Yoshimura of Ito Hospital for performing the genetic analysis of the anti-thyroid-stimulating hormone receptor antibody.

Funding
We have received no funding.

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article.

Authors’ contributions
NA wrote the manuscript. MI and TI treated the patient. HK and YM conducted the extensive work up. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Ethics approval and consent to participate
This case report involves a patient. The case report complies with the Declaration of Helsinki, and approval was obtained from the Ethics committee of Saiseikai Yokohamashi Tobu Hospital.

Author details
1Department of Neurosurgery, Saiseikai Yokohamashi, Tobu Hospital, Yokohama, Japan. 2Department of Endocrinology and Metabolism, Saiseikai Yokohamashi, Tobu Hospital, Yokohama, Japan.

Received: 26 August 2016 Accepted: 6 December 2016
Published online: 06 January 2017

References
1. Socin HV, Chanson P, Delerme B, Tabarin A, Rohner V, Mockel J, Stevensaert A, Beckers A. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003;148:433–42.
2. Kienitz T, Quinkler M, Strasburger CJ, Ventz M. Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature. Eur J Endocrinol. 2007;157:39–46.
3. O’Donnell J, Hadden DR, Weaver JA, Montgomery DA. Thyrotoxicosis recurring after surgical removal of a thyrotrophin-secreting pituitary tumour. Proc R Soc Med. 1973;66:641–2.
4. Sandler R. Recurrent hyperthyroidism in an acromegalic patient previously treated with proton beam irradiation: Graves’ disease as probable etiology based on follow-up observations. J Clin Endocrinol Metab. 1976;42:163–8.
5. Azukizawa M, Morimoto S, Miyai K, Miki T, Yabu Y, Amino N, et al. TSH-producing pituitary adenoma associated with Graves’ disease. In: Stockigt JR, Nagataki S, editors. Thyroid Research, vol. VII. Canberra: Australian Academy of Science; 1980. p. 645–8.
6. Kami K, Mitsuma T, Sato H, Yokoyama M, Washiyama K, Tanaka R, Arai O, Takasu N, Yamada T. Hyperthyroidism caused by a pituitary thyrotrophin-secreting tumour with excessive secretion of thyrotropin-releasing hormone and subsequently followed by Graves’ disease in a middle-aged woman. Acta Endocrinol (Copenh). 1985;110:573–82.
7. Koriyama N, Nakazaki M, Hashiguchi H, Aso K, Ikeda Y, Kimura T, Eto H, Hitano H, Nakano S, Ter C. Thyrotropin-producing pituitary adenoma associated with Graves’ disease. Eur J Endocrinol. 2004;151:587–94.
8. Lee MT, Wang CY. Concomitant Graves hyperthyroidism with thyrotropin-secreting pituitary adenoma. South Med J. 2010;103:347–9.
9. Ogawa Y, Tominaga T. Thyroid-stimulating hormone-secreting pituitary adenoma presenting with recurrent hyperthyroidism in post-treated Graves’ disease: a case report. J Med Case Rep. 2013;7:27.
10. Kamoun M, d’Herbomez M, Lemaire C, Fayard A, Desailloud R, Huglo D, Werneau JL. Coexistence of thyroid-stimulating hormone-secreting pituitary adenoma and graves’ hyperthyroidism. Eur Thyroid J. 2014;3:60–4.
11. Caldwell G, Kellett HA, Gow SM, Beckett GJ, Sweeting VM, Seth J, Toft AD. A new strategy for thyroid function testing. Lancet. 1985;1:1117–9.
12. Murata Y. Syndromes of resistance to thyroid hormone and inappropriate secretion of TSH (SITSH). Nihon Rinsho. 2012;70:1951–7.
13. Beck-Pecco P, Brucker-Davis F, Persani L, Smallridge RC, Wintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996;17:610–38.
14. Wintraub BD. Inappropriate secretion of thyroid-stimulating hormone. Ann Intern Med. 1981;95:339–51.
15. Ogawa Y, Tominaga T. A case of atypical thyrotrroph cell adenoma, which re-grew within 3 months after surgery and required multimodal treatment. J Neurooncol. 2008;87:91–5.